AZD1480

For research use only. Not for use in humans.

目录号：S2162

CAS No. 935666-88-9

AZD1480是一种新型，ATP竞争性的JAK2抑制剂，无细胞试验中IC50为0.26 nM，选择性作用于JAK3和Tyk2，对JAK1的作用较弱。Phase 1。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1071.19	现货
5mg	RMB 819.48	现货
50mg	RMB 4671.71	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的AZD1480发表文献85篇：

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 175(2):458-471

PubMed: 30173917 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):315-330

PubMed: 30033091 ( click the link to review the publication )

Cell Metab, 2017, 25(6):1320-1333

PubMed: 28591635 ( click the link to review the publication )

Nat Med, 2015, 21(1):47-54

PubMed: 25485912 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1205

PubMed: 33801977 ( click the link to review the publication )

Cancers (Basel), 2021, 13(7)1579

PubMed: 33808059 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(26):15047-15054

PubMed: 32532922 ( click the link to review the publication )

PLoS Biol, 2020, 18(3):e3000646

PubMed: 32203518 ( click the link to review the publication )

Clin Cancer Res, 2020,

PubMed: 32887724 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Oncogenesis, 2020, 10;9(2):15

PubMed: 32041943 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0186.2020

PubMed: 33004621 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1):e000285

PubMed: 32581055 ( click the link to review the publication )

Eur Arch Otorhinolaryngol, 2020, 10.1007/s00405-020-06274-3

PubMed: 32783069 ( click the link to review the publication )

Nat Commun, 2019, 10(1):716

PubMed: 30755611 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3601

PubMed: 31399589 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2808

PubMed: 31806641 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):85

PubMed: 30777101 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30634502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540495 ( click the link to review the publication )

Cell Death Discov, 2019, 5:72

PubMed: 30854231 ( click the link to review the publication )
Cancer Discov, 2019,

PubMed: 30366930 ( click the link to review the publication )

Front Immunol, 2019, 1.1243055556

PubMed: 31156620 ( click the link to review the publication )

Gastric Cancer, 2019, 22(3):486-496

PubMed: 30264329 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):384

PubMed: 31842997 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(6):4301-4312

PubMed: 30993883 ( click the link to review the publication )

Lab Invest, 2019, 99(12):1810-1821

PubMed: 31467427 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 316(3):L487-L497

PubMed: 30604628 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0254-4

PubMed: 31201357 ( click the link to review the publication )

J Microbiol Biotechnol, 2019, 29(12):2006-2013

PubMed: 31581384 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(10):1689-1704

PubMed: 31314158 ( click the link to review the publication )

Reproduction, 2019, 158(4):303-312

PubMed: 31408846 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30401677 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4345

PubMed: 30341316 ( click the link to review the publication )

Cancer Lett, 2018, 429:54-65

PubMed: 29729901 ( click the link to review the publication )

Metabolism, 2018, 79:10-23

PubMed: 29080813 ( click the link to review the publication )

Int J Obes , 2018, 42(2):252-259

PubMed: 28925407 ( click the link to review the publication )

J Cell Sci, 2018, 131(10)

PubMed: 29678906 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 314(5):L882-L892

PubMed: 29345196 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2018, 9:424

PubMed: 30140255 ( click the link to review the publication )

Int J Oncol, 2018,

PubMed: 30015925 ( click the link to review the publication )

Mol Immunol, 2018, 101:221-228

PubMed: 30007232 ( click the link to review the publication )

Molecules, 2018, 23(6)E1478

PubMed: 29921758 ( click the link to review the publication )

Blood, 2017, 129(14):1969-1979

PubMed: 28151428 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(11):2934-2939

PubMed: 28246332 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2017, 114(7):1643-1648

PubMed: 28130546 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

Oxid Med Cell Longev, 2017, 2017:7601592

PubMed: 29147463 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):852-861

PubMed: 28314843 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 29259270 ( click the link to review the publication )

Endocrinology, 2017, 158(7):2255-2268

PubMed: 28444169 ( click the link to review the publication )

Oncotarget, 2017, 8(53):91516-91529

PubMed: 29207662 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109319-109331

PubMed: 29312610 ( click the link to review the publication )

J Clin Invest, 2016, 126(4):1300-10

PubMed: 26927669 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

Small, 2016, 12(24):3270-82

PubMed: 27167493 ( click the link to review the publication )

Neuro Oncol, 2016, 10.1093/neuonc/now139

PubMed: 27402815 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(11):2758-2765

PubMed: 27566291 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2016, 14:119-27

PubMed: 26607555 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(1):9-23

PubMed: 26494904 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):57-67

PubMed: 25487280 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Sci Rep, 2015, 5:13414

PubMed: 26299368 ( click the link to review the publication )

Mol Pharmacol, 2015, 87(4):572-81

PubMed: 25583084 ( click the link to review the publication )

Mol Pharmacol, 2015, 87(4):572-81

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 458(4):908-12

PubMed: 25704089 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 458(4):908-12

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 8(48):83457-83468

PubMed: 29137356 ( click the link to review the publication )
Oncotarget, 2015, 6(29):28401-24

PubMed: 26315114 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )

Autophagy, 2014, 10(7):1212-28

PubMed: 24813621 ( click the link to review the publication )

J Med Chem, 2014, 57(15):6342-53

PubMed: 24978112 ( click the link to review the publication )

Oncol Rep, 2014, 32(5):1991-8

PubMed: 25216185 ( click the link to review the publication )

PLoS One, 2014, 9(10):e109799

PubMed: 25289677 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112014

PubMed: 25390891 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(42):16975-80

PubMed: 24082147 ( click the link to review the publication )

Cancer Lett, 2013, 341(2):224-30

PubMed: 23941832 ( click the link to review the publication )

Endocrinology, 2013, 154(9):3219-27

PubMed: 23782942 ( click the link to review the publication )

Asian Pac J Cancer Prev, 2013, 14(8):4823-7

PubMed: 24083752 ( click the link to review the publication )

Leukemia, 2012, 26(4):708-15

PubMed: 21926964 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(6):M112.017764

PubMed: 22345495 ( click the link to review the publication )

产品安全说明书

JAK抑制剂选择性比较

生物活性

产品描述

AZD1480是一种新型，ATP竞争性的JAK2抑制剂，无细胞试验中IC50为0.26 nM，选择性作用于JAK3和Tyk2，对JAK1的作用较弱。Phase 1。

特性

AZD1480为治疗多发性骨髓瘤的潜在新型治疗剂。

靶点

JAK2 ^[1]
(Cell-free assay)

0.26 nM

体外研究

5μM AZD1480诱导细胞周期停在G2/M期，且通过抑制Aurora激酶而诱导细胞死亡。^[1]AZD1480是JAK2的有效抑制剂，作用于人类多发性骨髓瘤细胞，可以抑制生长，存活，FGFR3 和 STAT3信号，及下游靶点，包括 Cyclin D2。在低微摩尔浓度时，AZD1480抑制细胞增殖和诱导骨髓瘤细胞系凋亡。^[2]AZD1480 作用于人和鼠神经胶质瘤细胞，有效抑制组成型和诱导型JAK1, JAK2, 及STAT-3的磷酸化作用，结果导致细胞增殖降低，且诱导凋亡。^[3]AZD1480是有效的ATP竞争性的JAK1/2激酶小分子抑制剂，可抑制STAT3磷酸化和肿瘤生长，这种抑制存在STAT3依赖性。AZD1480通过影响肿瘤的微环境而抑制肿瘤血管生成和局部转移。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SW620	NFn4OoFHfW6ldHnvckBCe3OjeR?=	NWHnRmNwPSEQvF2=	MoPwOFghcA>?	M2TNc2ROW09?	NHTnN4pjdG:la4OgTmFMOi:VVFHUN{B{cWewYXzpcoc>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl3NEm3OEc,OjV7NUS5O\|Q9N2F-
LoVo	NWn1b3d{TnWwY4Tpc44hSXO\|YYm=	NX\CbHBEPSEQvF2=	NUnqSY9NPDhiaB?=	NGexcpVFVVOR	NHHSWpVjdG:la4OgTmFMOi:VVFHUN{B{cWewYXzpcoc>	MkjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NUS5O\|QoRjJ3OUW0PVc1RC:jPh?=
HN5	M4nkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWe3NkBp		MXPFR\|UxRTNwOEGgxtEhOS57OTFOwG0>	NXvD[\|NIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVAxOTBpPkK1PFExODFyPD;hQi=>
Cal33	M2\iSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{LlelczKGh?		M3HrTGVEPTB;Mz6zO{DDuSByLke1JO69VQ>?	Mn;aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCwNVAoRjJ3OEGwNFExRC:jPh?=
UM-22B	Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnqwO\|IhcA>?		M4TpdGVEPTB;Mj62OkDDuSByLkK0JO69VQ>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMECxNEc,OjV6MUCwNVA9N2F-
686LN	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVW3NkBp		NFX0XIpGSzVyPUKuNFUhyrFiMT6zN{DPxE1?	NVr5bI5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVAxOTBpPkK1PFExODFyPD;hQi=>
UM SCC-1	M1X0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Moj2O\|IhcA>?		MYfFR\|UxRTFwNkegxtEhOC52MjFOwG0>	M1G3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwNFExLz5{NUixNFAyODxxYU6=
UM-22A	NHrYXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3\QTFczKGh?		MnjGSWM2OD1zLkOyJOKyKDBwM{mg{txO	NFL5SIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFAyOCd-MkW4NVAxOTB:L3G+
OSC19	NXXaNWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFf3ZWE4OiCq		MYDFR\|UxRTFwMk[gxtEhOC5{MDFOwG0>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMECxNEc,OjV6MUCwNVA9N2F-
PCI-52	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXXnR3JRPzJiaB?=		NYrDSFh4TUN3ME2xMlAxKMLzIECuNFkh\|ryP	MmT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCwNVAoRjJ3OEGwNFExRC:jPh?=
PCI-15B	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF3nXGM4OiCq		NV3jbJVOTUN3ME2wMlk6KMLzIEGuO\|Qh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMECxNEc,OjV6MUCwNVA9N2F-
UMSCC-1	MXPGeY5kfGmxbjDBd5NigQ>?	M13XZ\|AvODByNT2xMlYh\|ryP	Mm\FNlQhcA>?		MUXhZpJw\2G2ZYOgTWwuPuLCk3nu[JVk\WRidYCtdoVofWyjdHnvckBw\iCyU2TBWFNVgXJ5MEZCpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMECxNEc,OjV6MUCwNVA9N2F-
Cal33	M4\pO2Z2dmO2aX;uJGF{e2G7	NFr0XYwxNjByMEWtN{45KM7:TR?=	MXmyOEBp		MkPDZYJzd2ejdHXzJGlNNTckgKPpcoR2[2WmIIXwMZJm\3WuYYTpc44hd2ZicGPURXQ{XHm{N{C1xsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NYPNS41bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVAxOTBpPkK1PFExODFyPD;hQi=>
HH5	MlzPSpVv[3Srb36gRZN{[Xl?	NGXwXlUxNjByMEWtN{45KM7:TR?=	MknNNlQhcA>?		NFTEUmZi[nKxZ3H0[ZMhUUxvNvMAl4lv\HWlZXSgeZAuemWpdXzheIlwdiCxZjDwV3RCXDOWeYK3NFXDqGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M4X4d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwNFExLz5{NUixNFAyODxxYU6=
UM-22A	NW\kRW9ZTnWwY4Tpc44hSXO\|YYm=	NETveHoxNjByMEWtNU43KM7:TR?=	MnP0NlQhcA>?		NHvR[pli[nKxZ3H0[ZMhUUxvNvMAl4lv\HWlZXSgeZAuemWpdXzheIlwdiCxZjDwV3RCXDOWeYK3NFXDqGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NELnO5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFAyOCd-MkW4NVAxOTB:L3G+
A1847	MkfLSpVv[3Srb36gRZN{[Xl?	MWGwMlA2NTFyIN88US=>	NF7KU4EzPCCq	MY\EUXNQyqB?	MmD0doVlfWOnczDwbI9{eGixconsZZRm\CCVVFHUN{Bt\X[nbIO=	NY\1fIRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFYxOTVpPkK1OlQ3ODF3PD;hQi=>
OVCAR-5	NH\rcHhHfW6ldHnvckBCe3OjeR?=	NW\kVWV4OC5yNT2xNEDPxE1?	NWDSdlc1OjRiaB?=	NF33emVFVVORwrC=	NXPjW3hqemWmdXPld{BxcG:\|cHjvdplt[XSnZDDTWGFVOyCuZY\lcJM>	M4DVRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkS2NFE2Lz5{NU[0OlAyPTxxYU6=
OVCAR-8	M2XIVGZ2dmO2aX;uJGF{e2G7	NUHNTnY3OC5yNT2xNEDPxE1?	NGLNdJczPCCq	M3XLWGROW00EoB?=	M3nONJJm\HWlZYOgdIhwe3Cqb4L5cIF1\WRiU2TBWFMhdGW4ZXzz	NI\vPWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[0OlAyPSd-MkW2OFYxOTV:L3G+
MOVCAR-5447	NW\1dVAyTnWwY4Tpc44hSXO\|YYm=	NWnnSo0{OC5yNT2xNEDPxE1?	MkLWNlQhcA>?	NWLrZnZ{TE2VT9Mg	NFXFUWJz\WS3Y3XzJJBpd3OyaH;yfYxifGWmIGPURXQ{KGyndnXsdy=>	NWH4dHJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFYxOTVpPkK1OlQ3ODF3PD;hQi=>
MOVCAR-5009	M4rqbGZ2dmO2aX;uJGF{e2G7	MnziNE4xPS1zMDFOwG0>	NUHjT3dMOjRiaB?=	NXjjUHlbTE2VT9Mg	MXPy[YR2[2W\|IIDoc5NxcG:{eXzheIVlKFOWQWSzJIxmfmWucx?=	NVLMboRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFYxOTVpPkK1OlQ3ODF3PD;hQi=>
A1847	MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NYPsUlJKOC5yNT2xNEDPxE1?	MVO3NkBp	M4fKWGROW09?	MWjy[YR2[2W\|IHPlcIwhfmmjYnnsbZR6KGG2IITo[UBkd26lZYLueJJifGmxbjDv[kA2KM7:TR?=	NGPTelY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[0OlAyPSd-MkW2OFYxOTV:L3G+
OVCAR-5	NGGybYlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NULKO5E5OC5yNT2xNEDPxE1?	M{HENlczKGh?	NXPPeJM4TE2VTx?=	MoP0doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhPSEQvF2=	Ml[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NE[wNVUoRjJ3NkS2NFE2RC:jPh?=
OVCAR-8	NYm3ToFVS2WubDDWbYFjcWyrdImgRZN{[Xl?	NXzKTXdSOC5yNT2xNEDPxE1?	NVHuV\|RbPzJiaB?=	NFPzb5NFVVOR	NWe5TG9MemWmdXPld{Bk\WyuII\pZYJqdGm2eTDheEB1cGViY3;uZ4VzdnS{YYTpc44hd2ZiNTFOwG0>	NIrpSnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[0OlAyPSd-MkW2OFYxOTV:L3G+
OVCAR-5	M1rURmFxd3C2b4Ppd{BCe3OjeR?=	MoDqNE42NzFxNTFOwG0>	MnXQOFghcA>?	M{DIVWROW09?	M3z1eolv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITvd4l{KGG2IHjp[4gh[2:wY3XycpRz[XSrb36=	MoHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NE[wNVUoRjJ3NkS2NFE2RC:jPh?=
OVCAR-8	NVP3dGs6SXCxcITvd4l{KEG\|c3H5	NIHrfVAxNjVxMT:1JO69VQ>?	NFixU3A1QCCq	NYPobWR5TE2VTx?=	MXzpcoR2[2W\|IIPp[45q\mmlYX70JIFxd3C2b4Ppd{BifCCqaXfoJINwdmOncn70doF1cW:w	NEXNZ5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[0OlAyPSd-MkW2OFYxOTV:L3G+
AKRSL	NGTScm9E\WyuIG\pZYJqdGm2eTDBd5NigQ>?		NVq1WVB4PzJiaB?=		NGfBPWFKSzVy78{eNVAh\|ryP	NXrmN49QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NFQ3OzVpPkK1OVA1PjN3PD;hQi=>
PALJDL	NGLqRnpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?		NUjiWVIxPzJiaB?=		MnT0TWM2OD1{LkSg{txO	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVyNE[zOUc,OjV3MES2N\|U9N2F-
MO4	MlLoSpVv[3Srb36gRZN{[Xl?	NHfZblQxNjVxMT:1JO69VQ>?	NET3elk3KGh?		NVrXboZ3cW6qaXLpeJMhWC2VVFHUN{BmgHC{ZYPzbY9vyqB?	NYjLOmpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFk2OzVpPkK1NVQ6PTN3PD;hQi=>
DU145	MoLKSpVv[3Srb36gRZN{[Xl?	MWWwMVIxOCCwTR?=	MXmxJIjDqA>?		NXn1WXFWe3WycILld5NmeyCLTD22MYFkfGm4YYTl[EBUfGG2MzDhcoQhTVKNMT:yJJNq\26jbHnu[y=>	M4jVO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUe3PVQzLz5{NEW3O\|k1OjxxYU6=
DU145	MX7GeY5kfGmxbjDBd5NigQ>?	NUXJZlFFQDByIH7N	NUPoe2xYPzJiaB?=		M{XlPJN2eHC{ZYPz[ZMhUUxvNj3pcoR2[2WmIH3p[5JifG:{eR?=	M1qzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUe3PVQzLz5{NEW3O\|k1OjxxYU6=
CWR22Rv1	NHrRT3dHfW6ldHnvckBCe3OjeR?=	MkDVPFAxKG6P	M362cFczKGh?		MUjzeZBxemW\|c3XzJGlNNTZvaX7keYNm\CCvaXfyZZRwenl?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV5N{m0Nkc,OjR3N{e5OFI9N2F-
N592	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjLcHhPUUN3ME2wMlg1KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF3OEewNUc,OjRzNUi3NFE9N2F-
H82	NGPoO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTFwM{eg{txO	NHPxZ5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1PFcxOSd-MkSxOVg4ODF:L3G+
GLC4	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknRTWM2OD1zLke5JO69VQ>?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF3OEewNUc,OjRzNUi3NFE9N2F-
H526	NHq1NI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDQRZZKUUN3ME2zMlA5KM7:TR?=	M1rwRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUW4O\|AyLz5{NEG1PFcxOTxxYU6=
H1173	NWLJSY4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jRV2lEPTB;Mj6zPUDPxE1?	NEfLV4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1PFcxOSd-MkSxOVg4ODF:L3G+
DMS114	MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXxToRLUUN3ME2wMlc{KM7:TR?=	NFfGZok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1PFcxOSd-MkSxOVg4ODF:L3G+
NCI-N592	NHTYU5RHfW6ldHnvckBCe3OjeR?=	M1rlZVAvOy9zL{Og{txO	MlrwNlQhcA>?		NFKwdYZqdmS3Y3XzJGczN01iY3XscEBkgWOuZTDhdpJme3R?	NGfWNnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1PFcxOSd-MkSxOVg4ODF:L3G+
GLC4	NXHYUnIyTnWwY4Tpc44hSXO\|YYm=	Mn\oNE4{NzFxMzFOwG0>	Mk\CNlQhcA>?		NWnjNXNpcW6mdXPld{BIOi:PIHPlcIwh[3mlbHWgZZJz\XO2	MlfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUi3NFEoRjJ2MUW4O\|AyRC:jPh?=
NCI-H82	MWPGeY5kfGmxbjDBd5NigQ>?	MV[wMlMwOS9\|IN88US=>	Ml7INlQhcA>?		MnTpbY5lfWOnczDHNk9OKGOnbHygZ5lkdGViYYLy[ZN1	MofpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUi3NFEoRjJ2MUW4O\|AyRC:jPh?=
NCI-N592	NVjuWFhWSXCxcITvd4l{KEG\|c3H5	MWWwMlMwOS9\|IN88US=>	MVq0PEBp		NYfJSoljcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDjcIVifmWmLVPhd5Bie2ViMx?=	NHnROnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1PFcxOSd-MkSxOVg4ODF:L3G+
GLC4	MVPBdI9xfG:\|aYOgRZN{[Xl?	NHzUUXMxNjNxMT:zJO69VQ>?	Mm\GOFghcA>?		NIrVPFZqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIHPs[YF3\WRvQ3HzdIF{\SB\|	NWLUWo5KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVg4ODFpPkK0NVU5PzBzPD;hQi=>
NCI-H82	MmDTRZBweHSxc3nzJGF{e2G7	M375VFAvOy9zL{Og{txO	NIjWT241QCCq		MV;pcoNz\WG\|ZYOgeIhmKGyndnXsJI9nKGOuZXH2[YQuS2G\|cHHz[UA{	NFLDO4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1PFcxOSd-MkSxOVg4ODF:L3G+
CWR22Rv1	NFPwdVJCeG:ydH;zbZMhSXO\|YYm=				M4C3cWlEPTB;MD60PFIh\|ryP	MljQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NEKwPVUoRjJ\|OUSyNFk2RC:jPh?=
CWR22Pc	MmDjRZBweHSxc3nzJGF{e2G7				NFP5WpBKSzVyPUCuOFM5KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl2MkC5OUc,OjN7NEKwPVU9N2F-
PC-3	NV7BSXJJSXCxcITvd4l{KEG\|c3H5				M4Xkc2lEPTB;MT63OVUh\|ryP	M3;FeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUSyNFk2Lz5{M{m0NlA6PTxxYU6=
DU145	M3HH[GFxd3C2b4Ppd{BCe3OjeR?=				M1[weWlEPTB;Mz61NVch\|ryP	NVfobnNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFIxQTVpPkKzPVQzODl3PD;hQi=>
RC165N	MVLBdI9xfG:\|aYOgRZN{[Xl?				M1H1dmlEPTB;Mj6wPFMh\|ryP	M1frOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUSyNFk2Lz5{M{m0NlA6PTxxYU6=
ARPE19	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWTGWlNCTE2VTx?=	MUnJR\|UxRTJ2LkO4JO69VQ>?	MmPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
HEK293	NXTPfZN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{DCZmROW09?	M1WyNmlEPTB;OD62O{DPxE1?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
KCNR	NEnhWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2TmZ2ROW09?	M{OzWGlEPTB;MD60OkDPxE1?	M3iwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOxPVIyLz5{M{WzNVkzOTxxYU6=
SY5Y	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2DTTWROW09?	NEj2TGVKSzVyPUCuN\|Yh\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
BE2	NIHlU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXnpUXRITE2VTx?=	MWrJR\|UxRTBwN{Gg{txO	NGHTemM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
AS	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{Sx[WROW09?	NH7jdFhKSzVyPUGuOVMh\|ryP	NV7OdVBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
NGP	NWnxXZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkWySG1UVw>?	MkT6TWM2OD1yLkW2JO69VQ>?	NXvmfI5{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
IMR32	NWfLNm5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1vYVWROW09?	M4[0V2lEPTB;MD62OkDPxE1?	Mn;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
LAN5	NHy2PJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnTjSG1UVw>?	MVnJR\|UxRTFwMESg{txO	MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
RH18	NFv1UopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjEUXNQ	M1nSPGlEPTB;MT60NkDPxE1?	NWHOfnZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
RH30	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2f6[WROW09?	NXrRXotZUUN3ME2xMlI2KM7:TR?=	MlHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
RH17	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoHDSG1UVw>?	MlfZTWM2OD1{LkWxJO69VQ>?	NHPSfXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
RH28	NIDGXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFHTTGtFVVOR	NUXSeFBoUUN3ME20MlI5KM7:TR?=	M17CNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOxPVIyLz5{M{WzNVkzOTxxYU6=
RH36	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWjEUXNQ	MXvJR\|UxRTVwM{eg{txO	NXX4eWZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
RH41	NH;tXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NETqR2hFVVOR	MUjJR\|UxRTBwNEig{txO	NIPZ[IU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
RD	M3;vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX\EUXNQ	NESxR4lKSzVyPUSuN\|Ih\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
TC32	M1;SVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYnyXXlRTE2VTx?=	MkDrTWM2OD1\|Lki1JO69VQ>?	NYraZ\|ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
TC71	M3LKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1m4NWROW09?	M2fQUWlEPTB;ND6zN{DPxE1?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
KCNR	NX;WelJWSXCxcITvd4l{KEG\|c3H5	MXmwMlUwOS5yL{KuOUDPxE1?	MkPPNlQhcA>?	Mlq2SG1UVw>?	M1rUSIlv\HWlZYOgZY4hcW6lcnXhd4UhcW5iY3HzdIF{\SB\|L{egZYN1cX[rdIm=	M4\leFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOxPVIyLz5{M{WzNVkzOTxxYU6=
SY5Y	NYHnOZRLSXCxcITvd4l{KEG\|c3H5	Mm\QNE42NzFwMD:yMlUh\|ryP	NFvQb44zPCCq	NYnmTWliTE2VTx?=	NY[we\|hLcW6mdXPld{BidiCrbnPy[YF{\SCrbjDjZZNx[XOnIEOvO{Bi[3Srdnn0fS=>	NWnPdZZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
Rh18	NUPxT2c3SXCxcITvd4l{KEG\|c3H5	MXuwMlUwOS5yL{KuOUDPxE1?	MX6yOEBp	MlHDSG1UVw>?	NV7LSGg{cW6mdXPld{BidiCrbnPy[YF{\SCrbjDjZZNx[XOnIEOvO{Bi[3Srdnn0fS=>	NYnX[WMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
TC32	MUTBdI9xfG:\|aYOgRZN{[Xl?	MVOwMlUwOS5yL{KuOUDPxE1?	M{Swb\|I1KGh?	M1TTU2ROW09?	NIC1OYRqdmS3Y3XzJIFvKGmwY4LlZZNmKGmwIHPhd5Bie2ViMz:3JIFkfGm4aYT5	M37u[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOxPVIyLz5{M{WzNVkzOTxxYU6=
KCNR	MUDGeY5kfGmxbjDBd5NigQ>?	NUP2O5V5OC53L{GuNE8zNjVxNTFOwG0>	MlzzNlQhcA>?	MYXEUXNQ	MVrpcohq[mm2czDic5RpKGWwZH;n[Y5wfXNiY3;ud5RqfHW2aY\lJIFv\CCLTD22MYlv\HWlZXSgV3RCXDNiYXP0bZZifGmxbh?=	M1vRNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOxPVIyLz5{M{WzNVkzOTxxYU6=
SY5Y	NUTM[lBnTnWwY4Tpc44hSXO\|YYm=	MXSwMlUwOS5yL{KuOU82KM7:TR?=	MW[yOEBp	M1ThbmROW09?	M3zHe4lvcGmkaYTzJIJwfGhiZX7kc4dmdm:3czDjc45{fGm2dYTpeoUh[W6mIFnMMVYucW6mdXPl[EBUXEGWMzDhZ5RqfmG2aX;u	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
Rh18	NF3wOnhHfW6ldHnvckBCe3OjeR?=	MYSwMlUwOS5yL{KuOU82KM7:TR?=	NH76PJIzPCCq	M2DBS2ROW09?	MXrpcohq[mm2czDic5RpKGWwZH;n[Y5wfXNiY3;ud5RqfHW2aY\lJIFv\CCLTD22MYlv\HWlZXSgV3RCXDNiYXP0bZZifGmxbh?=	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
TC32	MlT4SpVv[3Srb36gRZN{[Xl?	MortNE42NzFwMD:yMlUwPSEQvF2=	MkDJNlQhcA>?	MnTFSG1UVw>?	NUDKeG1McW6qaXLpeJMh[m:2aDDlcoRw\2Wwb4XzJINwdnO2aYT1eIl3\SCjbnSgTWwuPi2rbnT1Z4VlKFOWQWSzJIFkfGm4YYTpc44>	M3roUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOxPVIyLz5{M{WzNVkzOTxxYU6=
TPC-1	NYXqSlFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYj1UZRCOSEEtV2=	MUOwMVQh\A>?	M3jt[2ROW09?	M3eyc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGGodHXyJFIh\CC2cnXheI1mdnR?	MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNU[0PVkoRjJ\|MEW2OFk6RC:jPh?=
MZ-CRC1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYKxJOK2VQ>?	NHOwPZIxNTViZB?=	NGDQZVdFVVOR	MkjkbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W[2ZYKgNUBlKHS{ZXH0cYVvfA>?	MkfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNU[0PVkoRjJ\|MEW2OFk6RC:jPh?=
TT	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS2NUDDvU1?	NHfsVmkxNTRiZB?=	NWnTV5k6TE2VTx?=	MmDWbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W[2ZYKgNUBlKHS{ZXH0cYVvfA>?	M2H6OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEW2OFk6Lz5{M{C1OlQ6QTxxYU6=
TPC-1	Mke3SpVv[3Srb36gRZN{[Xl?	NVvLfopyOSEEtV2=	MkLsO\|IhcA>?	Ml\uSG1UVw>?	NV7ub2J2cW6mdXPld{BIOSCkbH;jb4Fo\Q>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB3NkS5PUc,OjNyNU[0PVk9N2F-
MZ-CRC1	NF3qO2xHfW6ldHnvckBCe3OjeR?=	Mk\yNUDDvU1?	NX2zbmZ{PzJiaB?=	MYTEUXNQ	MmLIbY5lfWOnczDHNUBjdG:la3Hn[S=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB3NkS5PUc,OjNyNU[0PVk9N2F-
TT	M1LT[2Z2dmO2aX;uJGF{e2G7	M4jkfFEhyrWP	M3PVTlczKGh?	NHrTN5NFVVOR	NVvKV\|NVcW6mdXPld{BIOSCkbH;jb4Fo\Q>?	NWnQN\|hiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVY1QTlpPkKzNFU3PDl7PD;hQi=>
MZ-CRC1	M4LpVGFxd3C2b4Ppd{BCe3OjeR?=	M3vOO\|EhyrWP	M1\wN\|Q5KGh?	NYXtUmRmTE2VTx?=	M{n4Xolv\HWlZYOgZZBweHSxc3nz	NH3ZTVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1OlQ6QSd-MkOwOVY1QTl:L3G+
TT	M{XzS2Fxd3C2b4Ppd{BCe3OjeR?=	MnO1NUDDvU1?	MljCOFghcA>?	NVLSfIt[TE2VTx?=	MnrlbY5lfWOnczDhdI9xfG:\|aYO=	MonVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNU[0PVkoRjJ\|MEW2OFk6RC:jPh?=
HD-LM2	MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWO3NwKBkWh?	NYDqdHhZTE2VTx?=	M2nQOmlEPTB;Nz64OFQh\|ryP	NHPJXHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
L-428	M3TNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4fBR\|cz6oDLaB?=	M3[5NGROW09?	NGPCeW9KSzVyPUeuPVQ4KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{OUC5OEc,OjJ6MkmwPVQ9N2F-
KM-H2	M1fVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\GfFcz6oDLaB?=	MYHEUXNQ	NVjq[YZRUUN3ME2xMlMxQCEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{OUC5OEc,OjJ6MkmwPVQ9N2F-
L-540	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmCwO\|LjiImq	MkT1SG1UVw>?	MYjJR\|UxRThwMkG2JO69VQ>?	MofQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkmwPVQoRjJ{OEK5NFk1RC:jPh?=
HD-LM2	MnHISpVv[3Srb36gRZN{[Xl?	NGrXVFExNjFxMD61M\|EwPSEQvF2=	NIfBdng4OuLCiXi=	M4Wy[mROW09?	NXXLfGxZcW6qaXLpeJMhW1SDVEOsJHNVSVR3IHHu[EBUXEGWNjDwbI9{eGixconsZZRqd25?	NFTDWWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
L-428	NGrGeWlHfW6ldHnvckBCe3OjeR?=	NFvJeVAxNjFxMD61M\|EwPSEQvF2=	NEDMVWE4OuLCiXi=	M4PHWmROW09?	NHK0TplqdmirYnn0d{BUXEGWMzygV3RCXDViYX7kJHNVSVR4IIDoc5NxcG:{eXzheIlwdg>?	NFHkNJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
KM-H2	NHTO[JVHfW6ldHnvckBCe3OjeR?=	NV3TUHZsOC5zL{CuOU8yNzVizszN	NVz4e2NOPzMkgJno	MYnEUXNQ	MVvpcohq[mm2czDTWGFVOyxiU2TBWFUh[W6mIGPURXQ3KHCqb4PwbI9zgWyjdHnvci=>	MlPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkmwPVQoRjJ{OEK5NFk1RC:jPh?=
L-540	NWjJe3RNTnWwY4Tpc44hSXO\|YYm=	NHvrdpAxNjFxMD61M\|EwPSEQvF2=	MoH1O\|LjiImq	M3rYWmROW09?	M1\4SYlvcGmkaYTzJHNVSVR\|LDDTWGFVPSCjbnSgV3RCXDZicHjvd5Bpd3K7bHH0bY9v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{OUC5OEc,OjJ6MkmwPVQ9N2F-
HD-LM2	NVLjVlVnSXCxcITvd4l{KEG\|c3H5	NYOy[lRNOS93IN88US=>	MoCyO\|LjiImq	M1rLbWROW09?	NWnJTYgycW6mdXPld{BieG:ydH;zbZM>	M{DnR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK5NFk1Lz5{MkiyPVA6PDxxYU6=
L-428	NWSweYxkSXCxcITvd4l{KEG\|c3H5	NX\lWGdSOS93IN88US=>	M1L3[\|cz6oDLaB?=	MorZSG1UVw>?	NVG4XmlzcW6mdXPld{BieG:ydH;zbZM>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{OUC5OEc,OjJ6MkmwPVQ9N2F-
KM-H2	MoHFRZBweHSxc3nzJGF{e2G7	M13GUlEwPSEQvF2=	M2PjcFcz6oDLaB?=	MU\EUXNQ	MXTpcoR2[2W\|IHHwc5B1d3Orcx?=	NFTCPY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
L-540	NUXTS5lwSXCxcITvd4l{KEG\|c3H5	NXzkZnh{OS93IN88US=>	M3XSeFcz6oDLaB?=	NH7WTFJFVVOR	NEnxbItqdmS3Y3XzJIFxd3C2b4Ppdy=>	M4\mU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK5NFk1Lz5{MkiyPVA6PDxxYU6=
U251-MG	NGPOSXRHfW6ldHnvckBCe3OjeR?=	NVroUXo5OSEEtV2=	MUWwMVE3KGh?		M{TBZYlvcGmkaYTzJINwdnO2aYT1eIl3\SCVVFHUMVMh[W6mIFrBT\|Ih[WO2aY\heIlwdg>?	M3:5flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEK3OlkyLz5{MkCyO\|Y6OTxxYU6=
U87-MG	NHrGPXpHfW6ldHnvckBCe3OjeR?=	M3joS\|EhyrWP	NIXHVlUxNTF4IHi=		MmqwbY5pcWKrdIOgZ49ve3SrdIX0bZZmKFOWQWStN{BidmRiSlHLNkBi[3SrdnH0bY9v	M4rGdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEK3OlkyLz5{MkCyO\|Y6OTxxYU6=
4C8	M1TvdmZ2dmO2aX;uJGF{e2G7	NU\YZmpDOSEEtV2=	NWnvZYFxOC1zNjDo		NUfiUFdEcW6qaXLpeJMh[2:wc4TpeJV1cX[nIGPURXQuOyCjbnSgTmFMOiCjY4TpeoF1cW:w	M4fxXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEK3OlkyLz5{MkCyO\|Y6OTxxYU6=
U251-MG	NGX1fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzYcoUyNzFyINM1US=>	M{DrelI1NzR6L{eyJIg>		MVjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZZQh[SClb37j[Y51emG2aX;uJI9nKDFyINM1US=>	MlLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMke2PVEoRjJ{MEK3OlkyRC:jPh?=
U87-MG	MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXFUG57OS9zMDFCuW0>	M1XRdlI1NzR6L{eyJIg>		M4C3NolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBifCCjIHPvcoNmdnS{YYTpc44hd2ZiMUCgxtVO	MleyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMke2PVEoRjJ{MEK3OlkyRC:jPh?=
4C8	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6xM\|ExKML3TR?=	MmfINlQwPDhxN{KgbC=>		Mmf6bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIF1KGFiY3;uZ4VvfHKjdHnvckBw\iBzMDFCuW0>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{N{[5NUc,OjJyMke2PVE9N2F-
U266	Ml;yRZBweHSxc3nzJGF{e2G7	NY\le29XOC53LUKg{txO	NUK0WFg{PDhxN{KgbC=>		M4ftS4lv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	M4fQVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMU[0OVE4Lz5{MUG2OFUyPzxxYU6=
Kms.11	NIC2TYVCeG:ydH;zbZMhSXO\|YYm=	NHLXZWIxNjVvMjFOwG0>	MlXSOFgwPzJiaB?=		NHnVc\|lqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	NIO5bW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG2OFUyPyd-MkGxOlQ2OTd:L3G+
8226	NYf1XYV4SXCxcITvd4l{KEG\|c3H5	NWrKXmg1OC53LUKg{txO	MXm0PE84OiCq		M1LlUolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	MnXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNkS1NVcoRjJzMU[0OVE4RC:jPh?=
SET2	NX;Zc\|N4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1i4TFQ5KGi{cx?=		MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTSXQzKGOnbHzzJIV5eHKnc4PpcochUmGtMjDWOlE4TiCvdYThcpQh[W[2ZYKgOFghcHK\|IHL5JG1VWyCjc4PhfUwhT0l3MDC9JFAvODF4IN88UU4>	NGfUNYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
SET2	NH;sWpJHfW6ldHnvckBie3OjeR?=		NX30bJNIOSCqch?=		NF[wflRKdmirYnn0bY9vKG:oIGP0ZZQ{KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBUTVR{IHPlcIx{KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91fGmwZzygTWM2OCB;IECuNFI{KM7:TT6=	Ml3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
SET2	M1PBO2Z2dmO2aX;uJIF{e2G7		NH\vUXoyKGi{		M2LjU2lvcGmkaYTpc44hd2ZiU4TheFUheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHNGXDJiY3XscJMh[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5R1cW6pLDDJR\|UxKD1iMD6wNlUh\|ryPLh?=	Mn:1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
HEL	MUfGeY5kfGmxbjDhd5NigQ>?		NYLOd2Y2OSCqch?=		MYjJcohq[mm2aX;uJI9nKFO2YYS1JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDISWwh[2WubIOgZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4T0bY5oNCCLQ{WwJF0hOC5yNEGg{txONg>?	NEG2foI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
Ba/F3	NHnmZ5FHfW6ldHnvckBie3OjeR?=				NUH1eWZ4UW6qaXLpeIlwdiCxZjDTeIF1PSCyaH;zdIhwenmuYYTpc44hcW5ibX;1d4UhSmFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDUSWwuUmGtMjygTWM2OCB;IECuNFQ3KM7:TT6=	NUPyTpRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN\|gzPDZpPkKxNVM5OjR4PD;hQi=>
UKE1	Mnu0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{PRdVQ5KGi{cx?=		MUjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDVT2UyKGOnbHzzJIV5eHKnc4PpcochUmGtMjDWOlE4TiCvdYThcpQh[W[2ZYKgOFghcHK\|IHL5JG1VWyCjc4PhfUwhT0l3MDC9JFAvODV2IN88UU4>	NU\IWGFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN\|gzPDZpPkKxNVM5OjR4PD;hQi=>
BA/F3	NWLDe5dDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoTROFghcHK\|		MUTHdo94fGhiaX7obYJqfGmxbjDv[kBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3KRWszKGurbnHz[UBi\nSncjC0PEBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNE4xPiEQvF2u	Mnr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
HEL	Mkm4SpVv[3Srb36gZZN{[Xl?		NGm2[I4yKGi{		NXnRUXVnUW6qaXLpeIlwdiCxZjDTeIF1OyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUEWOIHPlcIx{KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91fGmwZzygTWM2OCB;IECuNFgh\|ryPLh?=	M1LOOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUO4NlQ3Lz5{MUGzPFI1PjxxYU6=
HEL	M{[0dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV:2Z2hUPDhiaILz		MoHZS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGVNKGOnbHzzJIV5eHKnc4PpcochUmGtMjDWOlE4TiCvdYThcpQh[W[2ZYKgOFghcHK\|IHL5JG1VWyCjc4PhfUwhT0l3MDC9JFAvOzlizszNMi=>	NEjRV5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
BA/F3	NHXUfWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{LaUlQ5KGi{cx?=		NYTrcWVlT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDU[YwuUkGNMTDrbY5ie2ViYX\0[ZIhPDhiaILzJIJ6KE2WUzDhd5NigSxiR1m1NEA:KDBwNzFOwG0v	Ml\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
BA/F3	NV7TS4RnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWi0PEBpenN?		NGjYZXZIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1VgWt{IHvpcoF{\SCjZoTldkA1QCCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwJF0hOiEQvF2u	NUHlW2JERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN\|gzPDZpPkKxNVM5OjR4PD;hQi=>
BA/F3	NXjRTIhNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUG4XWZJPDhiaILz		MWfHdo94fGhiaX7obYJqfGmxbjDv[kBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3KRWs{KGurbnHz[UBi\nSncjC0PEBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNk4yKM7:TT6=	NXXPXWRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN\|gzPDZpPkKxNVM5OjR4PD;hQi=>
UKE1	MnrTSpVv[3Srb36gZZN{[Xl?		NGSzS\|cyKGi{		NVHEW4hUUW6qaXLpeIlwdiCxZjDTeIF1PSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hXUuHMTDj[YxteyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfHSrbne=	NVPje\|VpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN\|gzPDZpPkKxNVM5OjR4PD;hQi=>
SW620	M4fuSmNmdGxiY4njcIUh[XO\|YYm=	Mmr1N{4{KHWP	M2rINVI1KGi{cx?=		MXfD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDTW\|YzOCClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDCzMlMhfU1iYX\0[ZIhOjRiaILzJIJ6KG[ub4egZ5l1d22ndIL5	Ml\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
HEL	NVSyXlRGTnWwY4Tpc44h[XO\|YYm=	MnziNE4{KHWP	NWnHfG14PSCvaX7z		M3;ZZ2lvcGmkaYTpc44hd2ZiU4TheFUheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGhGVCClZXzsd{BifCByLkOgeW0h[W[2ZYKgOUBucW6\|IHL5JHdme3Sncn6gZoxwfHSrbne=	MkHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
HEL	MYfGeY5kfGmxbjDhd5NigQ>?	NV3uZXNbOC5\|IIXN	MYGzNEB1dyB4MDDtbY5{		MVvJcohq[mm2aX;uJI9nKFO2YYS1JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDISWwh[2WubIOgZZQhOC5\|IIXNJIFnfGW{IEOwJJRwKDZyIH3pcpMh[nliV3XzeIVzdiCkbH;0eIlv\w>?	M1;KT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUO4NlQ3Lz5{MUGzPFI1PjxxYU6=
BA/F3	NIDvdnZCdnSrdIXtc5Ih[XO\|YYm=	NGjseo0{OCCvZz;r[y=>	MkfGNVIhcHK\|		MXLBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJHRmdC2MQVuyJJhmdm:pcnHmeIVlKGmwIF7DdkBud3W\|ZTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3SjdEWgcIV3\WxiaX6gd5Bt\WWwIHH0JFMxKG2pL3vnMEBxdyCjZoTldkAyOiCqcoOgZpkhX2W\|dHXyckBjdG:2dHnu[y=>	NITnNY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
HEL	MYTGeY5kfGmxbjDhd5NigQ>?	NVHyZo1NOC5\|IIXN	NWPjWFNkPSCvaX7z		M3\YbGlvcGmkaYTpc44hd2ZiU4TheFMheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGhGVCClZXzsd{BifCByLkOgeW0h[W[2ZYKgOUBucW6\|IHL5JHdme3Sncn6gZoxwfHSrbne=	MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
HEL	MkfJSpVv[3Srb36gZZN{[Xl?	Mn7zNE4{KHWP	M2HqRlMxKHSxIE[wJI1qdnN?		NXLn[WtFUW6qaXLpeIlwdiCxZjDTeIF1OyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUEWOIHPlcIx{KGG2IECuN{B2VSCjZoTldkA{OCC2bzC2NEBucW6\|IHL5JHdme3Sncn6gZoxwfHSrbne=	NILrOWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
Hs578T	MWDGeY5kfGmxbjDhd5NigQ>?	NUnGc4pXOSC3TR?=	MXyyOEBpenN?		M2\aPGlvcGmkaYTpc44hd2ZiU2TBWFNENW2nZHnheIVlKHS{YX7zZ5JqeHSrb36gbY4hcHWvYX6gTJM2PziWIHPlcIx{KGG2IEGgeW0h[W[2ZYKgNlQhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5OEGxNkc,OjR7N{ixNVI9N2F-
NCI-H1975	NFrHXmFHfW6ldHnvckBie3OjeR?=	NIn0XngxNjByMzD0c{A{KHWP	MVuyJIhzew>?		NFvSSmpKdmirYnn0bY9vKG:oIFrBT\|EhcW5iaIXtZY4hVkOLLVixPVc2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiMD6wNFMhfG9iMzD1UUBi\nSncjCyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NHHXcVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[xOFQxQCd-Mk[2NVQ1ODh:L3G+
HEL 92.1.7	NXS3e28xTnWwY4Tpc44h[XO\|YYm=		MUKyJIhzew>?		M4X5dmlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBJTUxiOUKuNU44KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDTWGFVPSCyaH;zdIhwenmuYYTpc44h[W[2ZYKgNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	Ml;yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MUS0NFgoRjJ4NkG0OFA5RC:jPh?=
DAOY	MlfxdWhVWyCjc4PhfS=>				M{ewOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	Mk\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	Mke1dWhVWyCjc4PhfS=>				Mof5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NFvudYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NGDreFlyUFSVIHHzd4F6				MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NWr2Z4VNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MkDvdWhVWyCjc4PhfS=>				MkP4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NEjUSoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NGPXcGJyUFSVIHHzd4F6				M{TqTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NXnvVIhIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NUTnWWNreUiWUzDhd5NigQ>?				M4To[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	NX25bJVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	Mn3YdWhVWyCjc4PhfS=>				NXjIU25teUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MmnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MmnxdWhVWyCjc4PhfS=>				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	MnT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	M1XORpFJXFNiYYPzZZk>				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	Mln5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	M3XHVJFJXFNiYYPzZZk>				MnLYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	MljRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	M4PDcJFJXFNiYYPzZZk>				MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	NGrTeWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MmLldWhVWyCjc4PhfS=>				M2fXW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	NHSzboY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NGf3RlVyUFSVIHHzd4F6				MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	Mk\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MmHadWhVWyCjc4PhfS=>				NWnjd3pseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT3 / STAT3 / p-JAK2 / JAK2 ; PubMed: 22027691 Mol Cancer Ther Cells were treated with AZD1480 for the indicated times, lysed and immunoblotted with the indicated antibodies. p-STAT1 / STAT1 / p-STAT5 / STAT5 / p-STAT6 / STAT6 ; PubMed: 22829094 Blood Cancer J Western blot assay of the four HL cell lines treated with increasing doses of AZD1480 (0.1–5 μM) for 72 h. p-ERK / ERK / p-p38 / p38 / SOCS3 / p-SHP2 / SHP2 ; PubMed: 22829094 Blood Cancer J Representative western blot assay showing increased levels of ERK, p38 and SHP-2 phosphorylation in HD-LM2 and L-428, after treatment for 72 h with increasing doses of AZD1480 (0.1-5 μM). In contrast, L-540 showed a dose-dependent inhibition of ERK and p38 activation without increased SHP-2 phosphorylation. SOCS-3 levels decreased in all the cell lines.	22027691 22829094
Immunofluorescence	pSTAT5; PubMed: 30140255 Front Endocrinol (Lausanne) HepG2 cells were incubated in the presence of Pro-Gly (0.5 mM) and/or AZD1480 (1 μM) for 6 h and phospho-STAT5 translocation to nuclei was detected by ICC. Scale bar, 10 μm. The IP and ICC experiments were conducted independently for 3 times, with 3 replicates each time.	30140255
Growth inhibition assay	Cell proliferation ; PubMed: 22027691 Mol Cancer Ther Cells were treated with AZD1480 for the indicated times, and the WST-1 cell proliferation assay performed. The 48 and 72 h time points were statistically significant. Data represent mean ± SD, replicates of three (**, p<0.001; ANOVA). Cell viability; PubMed: 25855603 Blood IL-3-independent Ba/F3 cells were treated with increasing concentrations of the JAK inhibitor AZD1480 showing submicromolar inhibition of proliferation.	22027691 25855603

体内研究

AZD1480作用于人类实体瘤模型和多发性骨髓瘤模型，抑制 STAT3磷酸化。^[1]在体内, AZD1480抑制皮下移植瘤的生长，且通过抑制STAT3活性提高携带颅内恶性胶质瘤(GBM)的鼠寿命，说明AZD1480抑制JAK/STAT3通路的药理学可以用于研究治疗携带颅内恶性胶质瘤的患者。^[3]AZD1480抑制骨髓细胞的肺浸润和肺转移瘤。AZD1480作用于人类移植瘤模型降低血管生成和代谢。^[4]AZD1480抑制含有STAT活性的人类实体瘤的生长。^[5]

激酶实验：^[5]	- 合并激酶实验: 在有buffer(包括50 mM HEPES pH 为7.3, 1 mM DTT, 0.01% Tween-20, 50 µg/ml BSA,及10 mM MgCl₂)的条件下，使用重组Jak1, Jak2, 或Jak3进行AZD1480抑制效果研究。在昆虫细胞中，Jak3酶表达为氮端GST融合蛋白，且通过谷胱甘肽亲和及尺寸排除色谱来纯化Jak3酶。加入AZD1480 (10点剂量反应, 重复三次, 8.3 µM 到0.3 nM )，使用1.5 µM 肽底物(Jak1:FITC-C6-KKHTDDGYMPMSPGVA-NH2, Jak2和Jak3: FAM-SRCtide)，及各自ATP K_m (Jak1: 55 µM, Jak2: 15 µM, Jak3: 3 µM)，ATP浓度为5 mM，进行酶实验。分离磷酸化和未磷酸化的肽段，使用Caliper LC3000系统计算抑制百分率。
细胞实验：^[4]	- 合并 Cell lines: Renca或786-O细胞，鼠内皮细胞和脾CD11b+/c−骨髓细胞, HUVECs Concentrations: 1 μM Incubation Time: 48或24小时 Method: Renca或786-O细胞悬浮在含5%FBS的DMEM培养基中,按每孔5×10³个细胞接种在96孔板上，使细胞粘附，实验组用AZD1480，对照组用DMSO，处理48小时。通过MTS实验测定细胞活力。使用Mikrotek Laborsysteme在490nm处测定吸光值。鼠内皮细胞和脾CD11b+/c− 骨髓细胞从携带肿瘤的鼠中富集得到，培养在含5% FBS的RPMI-1640培养基上。HUVECs 培养在胶原1包被的含完全培养基的板上。用DMSO和不同剂量AZD1480处理所有细胞，持续24小时。手动计算细胞数而测定细胞活力。所有实验重复三次。 (Only for Reference)
动物实验：^[4]	- 合并 Animal Models: 雌性BALB/c和无胸腺鼠(NCR− nu/nu) (7-8周大) Dosages: 每天一次，剂量为50 mg/kg；或者每天两次，剂量为30 mg/kg Administration: 口服饲喂 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	69 mg/mL warmed (197.83 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% propylene glycol	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download AZD1480 SDF

分子量	348.77
化学式	C₁₄H₁₄ClFN₈
CAS号	935666-88-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

泛JAK抑制剂

Ruxolitinib (INCB018424) : Pan JAK1/2 inhibitor, IC50=3.3 nM/2.8 nM.
FDA批准的JAK抑制剂

Tofacitinib (CP-690550,Tasocitinib) : Approved by FDA for rheumatoid arthritis (RA).
最新的JAK抑制剂

XL019 ^New : Potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2.
经典的JAK抑制剂

AG-490 (Tyrphostin B42) : Potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM; also potent to Aurora A/B, Abl(T315I). Phase 1/2.

研究领域

产品类型

定制您的化合物库

AZD1480

客户使用Selleck生产的AZD1480发表文献85篇：

产品安全说明书

JAK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download AZD1480 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

相关JAK产品